Retatrutide (LY3437943) is an investigational triple agonist that activates the GLP-1, GIP, and glucagon receptors. Among the questions we get most often from research customers is a simple one: why is it dosed weekly? The answer comes down to how the molecule was engineered and what its plasma half-life looks like in published Phase 1 and Phase 2 data.
This post is a plain-English walkthrough of the pharmacokinetics that drive retatrutide's dosing cadence. It is intended for research and educational purposes only. Nothing here is medical advice, and the compound is not approved for human use.
What "half-life" actually means
A drug's elimination half-life is the time it takes for plasma concentration to fall by half after absorption is complete. For peptide therapeutics, the half-life is shaped by three main factors:
- Proteolytic stability: how resistant the peptide backbone is to enzymes like DPP-4 that chew through native GLP-1 in minutes.
- Renal filtration: small peptides are cleared rapidly by the kidneys unless they are large enough or bound tightly enough to escape filtration.
- Albumin binding: many modern GLP-1 analogs carry a fatty-acid side chain that reversibly binds serum albumin, dramatically slowing clearance.
Retatrutide uses all three strategies. The native sequence is modified at positions that DPP-4 typically attacks, and a C20 fatty diacid linker tethers the peptide to albumin in circulation.
The reported numbers
Phase 1 single-ascending-dose work in healthy participants reported a mean terminal half-life of roughly six days for retatrutide. Phase 2 data in adults with obesity were consistent with that figure, supporting a once-weekly subcutaneous dosing schedule across the clinical program.
By contrast, native GLP-1 has a half-life measured in minutes. The difference is almost entirely an engineering story: albumin binding plus backbone modifications buy several orders of magnitude of circulating time without changing the receptor pharmacology.
Why it matters for protocol design
A six-day half-life has a few practical consequences worth noting in any research protocol:
- Steady state takes time. With weekly dosing, plasma levels typically approach steady state after roughly four to five weeks. Comparing endpoints before that point can be misleading.
- Missed doses don't crash levels. A skipped week reduces exposure but does not return the subject to baseline. This matters when interpreting washout periods in crossover designs.
- Titration smooths tolerability. Because the drug accumulates over weeks, starting at a low dose and stepping up, the strategy used in the TRIUMPH-2 program, gives the system time to adapt at each level.
Half-life is only one parameter, but it is the one that most directly explains why retatrutide looks and feels different from short-acting GLP-1 tools in the lab. Future posts will dig into receptor selectivity and the glucagon-arm contribution to energy expenditure.